Menu

1 / 3

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

Business - Latest - Google News·about 24 hours ago
#R3PJZh18
#world#news#nytimes#drug#summit
Reading 0:00
15s threshold

Advertisement

SKIP ADVERTISEMENT

You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

This X-ray shows stage 1 cancer. Summit Therapeutics of Florida had been seeking to bring to the U.S. market a drug for lung cancer, called ivonescimab, that was invented in China. Credit... James Cavallini/Universal Images Group, via Getty Images

Nov. 15, 2026, 3:33 p.m. ET

The Food and Drug Administration rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.

Summit Therapeutics, the Florida company that has been seeking to bring the drug to the American market, disclosed the agency’s decision in a news release on Sunday . Summit bought the U.S.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.